SUMMARY
At the ASH 2024 meeting in San Diego, there were over 200 oral presentations and more than 700 posters about multiple myeloma (MM). In contrast to the most recent ASH meetings were the major focus was on relapsed and refractory MM and more particularly on the newest data of the new generation of T-cell redirecting therapies like CAR-T cells and bispecific antibodies (BsAb), the oral sessions of the current ASH edition were more focused on newly diagnosed (ND) MM patients and on the growing importance of minimal residual disease (MRD). This paper summarises some of the MM ‘highlights’. Since this paper is not intended to give a comprehensive summary of the several hundreds of papers, I would like to acknowledge all clinicians and researchers who have contributed abstracts to this ASH congress and in particular our Belgian colleagues.
(BELG J HEMATOL 2025;16(1):4–6)
